Lexicon Pharmaceuticals (NASDAQ:LXRX) Given "Buy" Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX - Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. HC Wainwright currently has a $4.00 target price on the biopharmaceutical company's stock.

Other equities research analysts have also recently issued reports about the company. Leerink Partners set a $6.00 target price on Lexicon Pharmaceuticals and gave the stock an "outperform" rating in a report on Friday, October 18th. Needham & Company LLC reissued a "hold" rating on shares of Lexicon Pharmaceuticals in a research report on Monday, December 23rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $5.00.

Lexicon Pharmaceuticals Price Performance

NASDAQ:LXRX traded down $0.00 during trading hours on Wednesday, hitting $0.82. The stock had a trading volume of 2,946,477 shares, compared to its average volume of 5,808,694. The company has a 50 day simple moving average of $0.79 and a two-hundred day simple moving average of $1.38. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43. The firm has a market capitalization of $202.66 million, a price-to-earnings ratio of -1.10 and a beta of 1.06. Lexicon Pharmaceuticals has a one year low of $0.62 and a one year high of $3.73.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.01). The firm had revenue of $1.75 million during the quarter, compared to the consensus estimate of $3.14 million. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. During the same quarter in the previous year, the firm earned ($0.21) EPS. Research analysts forecast that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. FMR LLC boosted its stake in shares of Lexicon Pharmaceuticals by 28.9% in the third quarter. FMR LLC now owns 49,867,042 shares of the biopharmaceutical company's stock worth $78,291,000 after buying an additional 11,179,919 shares during the last quarter. Point72 Asset Management L.P. boosted its position in Lexicon Pharmaceuticals by 605.2% in the 2nd quarter. Point72 Asset Management L.P. now owns 4,121,191 shares of the biopharmaceutical company's stock worth $6,924,000 after purchasing an additional 3,536,805 shares in the last quarter. Marshall Wace LLP grew its stake in shares of Lexicon Pharmaceuticals by 138.5% during the 2nd quarter. Marshall Wace LLP now owns 1,190,448 shares of the biopharmaceutical company's stock worth $2,000,000 after purchasing an additional 691,276 shares during the period. Geode Capital Management LLC increased its holdings in shares of Lexicon Pharmaceuticals by 8.4% during the 3rd quarter. Geode Capital Management LLC now owns 3,523,971 shares of the biopharmaceutical company's stock valued at $5,534,000 after purchasing an additional 273,436 shares in the last quarter. Finally, BBR Partners LLC lifted its stake in shares of Lexicon Pharmaceuticals by 74.1% in the 3rd quarter. BBR Partners LLC now owns 470,000 shares of the biopharmaceutical company's stock valued at $738,000 after purchasing an additional 200,000 shares during the period. 74.70% of the stock is currently owned by institutional investors and hedge funds.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.